Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riluzole for psychotic and cognitive symptoms in 22q11.2 deletion syndrome
2021-002011-61Phase 3Completed
- Sponsor
- Maastricht University Medical Center+
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of riluzole in Velocardiofacial syndrome (VCFS), Schizophrenia Spectrum Disorders (SSD) and confusion, sponsored by Maastricht University Medical Center+. Primary endpoints: Change in psychotic symptom severity and Change in cognitive symptom severity. Started Jun 2021; status: completed.
02
Drugs
riluzole
03
Conditions
Velocardiofacial syndrome (VCFS)Schizophrenia Spectrum Disorders (SSD)confusion
Beyond the preview
Go deeper on 2021-002011-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002011-61.